Compare GeneDx Holdings Corp (WGS) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Exxon Mobil Corporation — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.56B), while Exxon Mobil Corporation trades at $165.63 (market cap $660.62B). The key difference: Exxon Mobil Corporation is far larger — about 258.1× GeneDx Holdings Corp's market cap, and Exxon Mobil Corporation pays a 2.56% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| WGS | XOM | |
|---|---|---|
Market Cap | $2.56B | $660.62B |
Sector | Technology | Energy |
52-Week High | $167.51 | $171.52 |
52-Week Low | $34.51 | $110.64 |
Enterprise Value | $2.60B | $692.40B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
ExxonMobil (XOM) trades at $164.26, up 3.01% today, with a neutral technical signal and bullish moving averages. The stock shows solid profitability with a 9.07% net margin and 12.55% ROE, though revenue and net income have declined from 2022 peaks. Recent earnings beat estimates in two of the last three quarters, with Q3 2026 results pending. Analyst consensus is a $168.14 price target, with 39% buy ratings. News highlights Exxon's Permian Basin strength and warnings of potential oil price spikes to $160.
XOM offers value with a P/E of 20.68 and strong cash flow, but faces risks from volatile oil prices and declining margins. The dividend provides income, yet geopolitical tensions and energy transition pressures pose challenges. Upside depends on execution in the Permian and oil market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
